Amicus Therapeutics’ (FOLD) “Hold” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of Amicus Therapeutics (NASDAQ:FOLD) in a research note issued to investors on Thursday morning,Benzinga reports.

FOLD has been the subject of a number of other research reports. Morgan Stanley reiterated an “equal weight” rating and set a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Guggenheim increased their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. increased their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Cantor Fitzgerald reiterated an “overweight” rating and set a $21.00 target price on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Finally, StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $16.75.

Amicus Therapeutics Price Performance

Shares of NASDAQ FOLD opened at $9.19 on Thursday. The firm has a market capitalization of $2.82 billion, a P/E ratio of -51.06, a PEG ratio of 1.51 and a beta of 0.61. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. Amicus Therapeutics has a one year low of $8.78 and a one year high of $14.02. The company’s fifty day moving average is $9.56 and its two-hundred day moving average is $10.41.

Insider Activity at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total value of $75,150.00. Following the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $8,884,273.08. This trade represents a 0.84 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 2.20% of the stock is owned by company insiders.

Institutional Trading of Amicus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP grew its holdings in shares of Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock worth $255,936,000 after purchasing an additional 2,856,101 shares in the last quarter. Tempus Wealth Planning LLC bought a new position in shares of Amicus Therapeutics during the 4th quarter worth approximately $259,000. Neo Ivy Capital Management bought a new position in shares of Amicus Therapeutics during the 3rd quarter worth approximately $702,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Amicus Therapeutics by 51.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 222,934 shares of the biopharmaceutical company’s stock worth $2,381,000 after buying an additional 75,807 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in Amicus Therapeutics by 10.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,667,271 shares of the biopharmaceutical company’s stock valued at $28,486,000 after purchasing an additional 242,672 shares during the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.